Company / Shareholders' Equity
Arcus Biosciences, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$631.0M
FY2025
5-year range
$462.0M / $842.0M
FY2021-FY2025
Trend
+30.1%
vs FY2024
Sector context
#76 of 213
Health Care
What the data says
At $631M, Arcus Biosciences, Inc.'s shareholders' equity ranks #76 of 213 in the Health Care sector. Improved from $462M to $631M over the past 2 years.
Based on SEC 10-K filings.
$631M in FY2025 with a 5-year CAGR of +21.8%.
Improved from $462M to $631M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +7.9%
- 5-Year CAGR
- +21.8%
- 10-Year CAGR
- -
Sector benchmark
#76 of 213 in Health CareTop 36% of 213This company $631.0M Sector average $2.5B
▼
-75.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.8%, indicating consistent growth.
- In FY2025, shareholders' equity increased 30.1% year-over-year.
- Ranks #76 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $631.0M | +30.1% |
| FY2024 | $485.0M | +5.0% |
| FY2023 | $462.0M | -8.0% |
| FY2022 | $502.0M | -40.4% |
| FY2021 | $842.0M | +258.4% |
| FY2020 | $234.9M | +43.3% |
| FY2019 | $164.0M | +326.7% |
| FY2018 | -$72.3M | +0.0% |
| FY2017 | -$72.3M | -261.7% |
| FY2016 | -$20.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026